ACAD

AI Memo

ACADIA

As of 2026-05-20/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-20 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Q1 2026 results and FY2026 guidance reaffirmed [#8-K-2026-05-06] • 2026-05-06

Expected move: +29%

Biggest risk

SG&A stepped up sharply, Q1 EPS was only $0.02 despite $268M of revenue, and the thesis still depends on a small set of commercial assets plus binary clinical outcomes; any slowdown in DAYBUE or weak readouts would pressure the stock.

Invalidation

Break below $15 or thesis failure.

What would change my mind?

DAYBUE is growing, NUPLAZID remains resilient, management reaffirmed FY2026 guidance, and the company has two dated 2H2026 program milestones supported by the May 2026 8-K exhibit.

Research note

Recommendation

—

Confidence

medium

As of

2026-05-20

Base target

$28

p=50%

Bull target

$34

p=25%

Bear target

$15

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Remlifanserin Phase 2 topline readout in Alzheimer disease psychosis [#8-K-2026-05-06]
Trofinetide Japan trial topline results [#8-K-2026-05-06]
DAYBUE is growing, NUPLAZID remains resilient, management reaffirmed FY2026 guidance, and the company has two dated 2H2026 program milestones supported by the May 2026 8-K exhibit.

BearKey bullets

Both remlifanserin and the Japan trofinetide program are binary catalysts; negative data would likely compress the multiple.
Commercial expense growth is steep: SG&A rose to $171M from $126M, limiting operating leverage.
The stock depends heavily on DAYBUE/NUPLAZID performance, so any launch slowdown or prescription softness would matter quickly.

WatchKey bullets

Q1 2026 results and FY2026 guidance reaffirmed [#8-K-2026-05-06]

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $28 (p=50%)

Bull/Bear spread: +57% / -31%

Vs latest close: Bull +57% · Base +29% · Bear -31%

Scenario probabilities

Bull Target: $34 (p=25%)Base Target: $28 (p=50%)Bear Target: $15 (p=25%)

Commentary

Primary-source tone is constructive because revenue grew, both marketed products contributed, guidance was reaffirmed, and the May 2026 8-K exhibit identifies two dated 2H2026 program milestones. The offset is higher commercial spending, modest Q1 earnings power, and limited visible analyst-revision support in the packet. No social-context signal was available, so sentiment should not override the cautious primary-source monitoring view.

As of 2026-05-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

DAYBUE is growing, NUPLAZID remains resilient, management reaffirmed FY2026 guidance, and the company has two dated 2H2026 program milestones supported by the May 2026 8-K exhibit.

Bear Case

Drivers

Scannable catalysts and supporting factors

Remlifanserin Phase 2 topline readout in Alzheimer disease psychosis [#8-K-2026-05-06]
Trofinetide Japan trial topline results [#8-K-2026-05-06]

Scenarios

Bull Target (Scenario probability)

$34 / p=25% prob

Base Target (Scenario probability)

$28 / p=50% prob

Bear Target (Scenario probability)

$15 / p=25% prob

Price $22 as of 2026-05-28

Nearest Scenario: Base (∆ 29%)

Targets vs latest close: Bull +57% · Base +29% · Bear -31%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-06
Q1 2026 results and FY2026 guidance reaffirmed [#8-K-2026-05-06]
Acadia reported total revenue of $268M, DAYBUE sales of $101M (+20% y/y), NUPLAZID sales of $167M (+6% y/y on a non-GAAP adjusted basis), net income of $4M, and reaffirmed full-year 2026 guidance; the offset was much higher SG&A at $171M vs. $126M a year ago.
Prob 95.00% • Move 3.50% • Priced-in 72.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Remlifanserin Phase 2 topline readout in Alzheimer disease psychosis [#8-K-2026-05-06]
2026-09-15
The company said Phase 2 topline results for remlifanserin in Alzheimer disease psychosis remain on track for the August to October 2026 timeframe. This is a company-specific forward catalyst, but it is binary and should be treated as a monitoring item rather than a confirmed positive driver.
Prob 50% • Move 8% • Priced-in 38%
Trofinetide Japan trial topline results [#8-K-2026-05-06]
2026-10-15
Acadia said accelerated enrollment in the trofinetide clinical trial in Japan moved expected topline results to the September to November 2026 timeframe, giving the stock a second dated program-specific milestone in 2H2026.
Prob 45% • Move 5% • Priced-in 30%

Risks

Both remlifanserin and the Japan trofinetide program are binary catalysts; negative data would likely compress the multiple.
Commercial expense growth is steep: SG&A rose to $171M from $126M, limiting operating leverage.
The stock depends heavily on DAYBUE/NUPLAZID performance, so any launch slowdown or prescription softness would matter quickly.
There is limited visible post-print analyst re-rating in the packet, so a stronger rerating thesis lacks confirmation.

Peers

Symbol	Summary
OGN	Similar-sized commercial pharma with existing marketed products; useful for comparing execution, margins, and launch durability, though therapeutic overlap is limited.
CRNX	Mid-cap biopharma with catalyst-driven valuation sensitivity; useful for reading broader biotech risk appetite, but it is less commercial-stage than ACAD.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-20

Loading AI feed…

Symbol

Summary

OGN

Similar-sized commercial pharma with existing marketed products; useful for comparing execution, margins, and launch durability, though therapeutic overlap is limited.

CRNX

Mid-cap biopharma with catalyst-driven valuation sensitivity; useful for reading broader biotech risk appetite, but it is less commercial-stage than ACAD.